The first clinical trial measuring IA autologous CD34+ stem cell delivery in human ischaemic stroke patients found that intervention was well tolerated by all participants (primary outcome measure), with improvements in clinical function characterised by a significant decrease in mean NIHSS score from 10.40 to 2.20 (95% CI; 3.69–12.71; p = 0.007) [128]. The gene discussed is CD34; the disease is ischemic stroke.